Business
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and
About this update from Annexon, Inc.
[{"type":"image","alt":"Annexon Biosciences","displaySize":"","headline":null,"caption":"Annexon Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/578fc108e7e0712a28769323578aa13e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J35LGkHzjL3FW6lOBPAtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/578fc108e7e0712a28769323578aa13e","width":300,"height":99}},"lazy":false},{"type":"text","content":"Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)","length":172,"tagName":"p"},{"type":"text","content":"Phase 3 ARCHER II Trial Enrolling Globally","length":42,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on the neuroprotective effect of ANX007, including consistent benefits of C1q inhibition against inflammation and neuronal damage across diseases. The presentations will take place at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held May 4-8 in Salt Lake City, Utah and at the 2025 Retina World Congress being held May 8-11 in Fort Lauderdale, Florida.","length":717,"tagName":"p"},{"type":"text","content":"ANX007 is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. ANX007 is the only investigational therapy in GA to show significant vision preservation on the endpoints of best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA).","length":331,"tagName":"p"},{"type":"text","content":"ARVO Annual Meeting Poster Presentation“Microglia-induced neuronal injury attenuation with C1q Inhibition: Outcomes in Geographic Atrophy (GA) and Huntington’s Disease (HD)”","length":175,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presenter: Ajay E. Kuriyan, M.D., Retina Specialist, Wills Eye Hospital and Associate Professor ...